A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors. ClinicalTrials.gov record last updated 2025-09-24: recruiting. Enrollment is planned at 300 participants. Primary completion is estimated at 2027-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: LCB84, Anti-PD-1 monoclonal antibody. Registered primary measures: Safety of LCB84 alone and LCB84 in combination with an anti-PD-1 Ab (Phase 1 and 2); Recommended Phase 2 Dose of LCB84 alone and LCB84 in combination with an anti-PD-1 Ab (Phase 1); Objective Response Rate (Phase 2).